|Description||An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females. [Pubchem]|
|DrugBank||Primary Accession Number: DB04839|
|Type||Approved, Investigational, Small Molecule|
|Indication||For the palliative treatment of patients with advanced prostatic carcinoma.|
|Mechanism of Action||The direct antiandrogenic effect of cyproterone is blockage of the binding of dihydrotestosterone to the specific receptors in the prostatic carcinoma cell. In addition, cyproterone exerts a negative feed-back on the hypothalamo-pituitary axis, by inhibiting the secretion of luteinizing hormone resulting in diminished production of testicular testosterone.|
|Absorption||Completely absorbed following oral administration.|
You need to load/activate the cURL extension (http://www.php.net/cURL).
|Protein Binding||Not available|